SoftOx Solutions (Part 1)

[Melhus79]

Nå bør alt ligge tilrette til vekst.

[Aaleby]

Oppdatert i dag uten at dato er forandret:

Hygieneprodukter

[Sponplate]

Såvidt jeg kan se har de kun fjernet en av kontaktpersonene.

[TekBot]

SoftOx Solutions AS: Share issuance to employees

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 16 February 2021 regarding the employee offering.

The Board of Directors has resolved to issue a total of 164,348 new shares, each with a nominal value of NOK 0.02, to employees who had applied for shares. The shares were issued under a board authorization granted by the Company’s general meeting on 4 January 2021.
…

Vis børsmeldingen

The new shares were issued at a subscription price of NOK 55, resulting in gross proceeds of approx. NOK 9,039,140.
The following primary insiders subscribed and were allocated shares in the Employee Offering:

• Melvin Teigen (chairman) has subscribed for 10,000 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Teigen holds 16,000 shares in the Company.

• Geir Almås (CEO) has, through his holding company Hermod Farms AS, subscribed for 36,360 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Almås together with his close associates holds 861 473 shares in the Company.

• Kristine Rød (CFO) has subscribed for 3,637 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Rød holds 3,637 shares in the Company.

• Primary insider Hans Petter Grette has, through his holding company Renholdsprodukter AS, subscribed for 7,288 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Grette together with his close associates holds 90,000 shares in the Company.

• Primary insider Glenn Gundersen has subscribed for 4,550 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Gundersen holds 10,550 shares in the Company.

• Primary insider Elisabeth Ahlmann Ohlsen has subscribed for 200 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Ohlsen holds 200 shares in the Company.

• Primary insider Dag Abrahamsen has, through his holding company Genesis Holding AS, subscribed for 3,636 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Abrahamsen holds 3,636 shares in the Company.

The shares will be delivered through VPS and will be admitted to trading on Euronext Growth Oslo following the registration of the shares in the Norwegian Register of Business Enterprises (Nw: Foretaksregisteret).

This announcement is made under the Norwegian Securities Trading Act Section 4-2.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, FM of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

Kilde

[Melhus79]

Er ikke dette tidligere meldt ?

[prump]

Det ser da ut som samme melding som ble gitt 24/2.

[polsmannen]

Det er nesten sånn at jeg begynner å mistenke disse utsettelsene kommer av den ventende godkjennelsen til Softox…

[alfred_e_neuman]

Dette er en korrigert versjon av meldingen som kom 24. februar. De har redusert antall aksjer under Geir Almås.

24.02.2021, 20:50:29
Almås together with his close associates holds 989,072 shares in the Company.

01.03.2021, 10:37:57
Almås together with his close associates holds 861 473 shares in the Company.

[solskimm]

@polsmannen

Det er nesten sånn at jeg begynner å mistenke disse utsettelsene kommer av den ventende godkjennelsen til Softox…

Hvem er det vi venter på, er det REK / Statens helsetilsyn?

[polsmannen]

Aner ikke hvem som godkjenner

[Geirbjarne]

Ny børsmelding etter slutt idag. Føler det på meg.

[solskimm]

@Geirbjarne

Føler det på meg.

[cagey2]

Etter uker og måneder med kursmessig så var det plutselig voldsomt til action da. Jaja, jeg regner med dette bare viser forsmaken på hva som kommer videre. Skal bli morro dette!

[M73102]

Jeg vet ikke polsmannen - men Softox har vel ikke tidligere hatt praksis å børsmelde verken første innrullet pasient/oppstart, ref swis 2. Ser ut tilå være mange likheter med SIS - men en kan vel ikke kommet så langt allerede 1. mars (selv om en har kommunisert at en jobber hardt for å starte tidligere enn mars)?

[Aakam]

Var det ikke snakk om at inhalator skulle testes på mennesker ila mars, mht effekt? Da må vel safety på plass i forkant. Så dette kan stemme!

[polsmannen]

Er veldig usikker men…så er de fase 1 clinic også??
-We perform a wide range of clinical studies in our 10-bed fully equipped clinical pharmacology research unit located at Copenhagen University Hospital, Bispebjerg.

[polygon]

De skriver at det er 64 forsøkspersoner de har rekruttert. SoftOX har 40.

https://www.dantrials.com/media-centre.html

Edit: Men før jeg så det, så sendte jeg en mail og spurte - og etter jeg skrev det over fikk jeg svar:

Tak for din email. NCT koden for studiet er NCT04576312.

Torben

Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy...

[polsmannen]

Da blir det 24 for mye. altså ikke Softox og herved avklart.

Den UNI911 Så jeg også mens jeg har holdt på her…

[M73102]

Takk. Det var i Swis 2 selskapet hadde 40 pasienter. I SIS skal de ha 64 pasienter - se lenken du vedla.

[polsmannen]

Yepp så det, da kan det faktisk være noe i denne jeg la ut likevell

Actual Enrollment : 64 participants